• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于淋巴细胞亚群绝对计数的临床列线图,用于预测非小细胞肺癌患者的总生存期。

A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.

作者信息

Liu Aqing, Zhang Guan, Yang Yanjie, Xia Ying, Li Wentao, Liu Yunhe, Cui Qian, Wang Dong, Zhao Jian, Yu Jianchun

机构信息

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China; Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.

出版信息

Int Immunopharmacol. 2023 Jan;114:109391. doi: 10.1016/j.intimp.2022.109391. Epub 2022 Dec 9.

DOI:10.1016/j.intimp.2022.109391
PMID:36508919
Abstract

BACKGROUND

The absolute count of lymphocyte subsets (ACLS) is correlated to the prognosis of multiple malignancies. This study aimed to combine the ACLS with the clinicopathological parameters to develop a nomogram to accurately predict the prognosis of non-small cell lung cancer (NSCLC) patients.

METHODS

This retrospective study included a training cohort (n = 1685) and validation cohort (n = 337) with NSCLC patients treated in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine between January 2018 and January 2021. Cox regression were conducted to identify factors associated with overall survival. The nomogram was built based on 10 significant factors, and evaluated by the concordance index (C-index), calibration curve and receiver operating characteristic (ROC) curve.

RESULTS

In the training cohort, the multivariate cox proportional hazard regression analysis showed that the independent factors for overall survival (OS) included age, brain metastases, hepatic metastases, respiratory system diseases, clinical stages, surgery, absolute count (AC) of CD3, CD4, CD8, and NK cells, which were all applied in the nomogram. The C-index of the nomogram to predict OS was 0.777 (95% CI, 0.751-0.802) in training cohort and 0.822 (95% CI, 0.798-0.846) in validation cohort. The area under the ROC showed a good discriminative ability in both cohorts. Calibration curves presented an excellent consistence between the nomogram predicted probability and actual observation.

CONCLUSIONS

We established a prognostic nomogram to predict OS of the NSCLC patient. This nomogram provided a more quantitative, scientific and objective basis for accurate diagnosis and individual management of NSCLC patients.

摘要

背景

淋巴细胞亚群绝对计数(ACLS)与多种恶性肿瘤的预后相关。本研究旨在将ACLS与临床病理参数相结合,开发一种列线图,以准确预测非小细胞肺癌(NSCLC)患者的预后。

方法

这项回顾性研究纳入了2018年1月至2021年1月在天津中医药大学第一附属医院接受治疗的NSCLC患者的训练队列(n = 1685)和验证队列(n = 337)。进行Cox回归以确定与总生存相关的因素。基于10个显著因素构建列线图,并通过一致性指数(C指数)、校准曲线和受试者工作特征(ROC)曲线进行评估。

结果

在训练队列中,多因素Cox比例风险回归分析显示,总生存(OS)的独立因素包括年龄、脑转移、肝转移、呼吸系统疾病、临床分期、手术、CD3、CD4、CD8和NK细胞的绝对计数(AC),这些因素均应用于列线图中。训练队列中列线图预测OS的C指数为0.777(95%CI,0.751 - 0.802),验证队列中为0.822(95%CI,0.798 - 0.846)。ROC曲线下面积在两个队列中均显示出良好的鉴别能力。校准曲线显示列线图预测概率与实际观察之间具有良好的一致性。

结论

我们建立了一种预测NSCLC患者OS的预后列线图。该列线图为NSCLC患者的准确诊断和个体化管理提供了更定量、科学和客观的依据。

相似文献

1
A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer.一种基于淋巴细胞亚群绝对计数的临床列线图,用于预测非小细胞肺癌患者的总生存期。
Int Immunopharmacol. 2023 Jan;114:109391. doi: 10.1016/j.intimp.2022.109391. Epub 2022 Dec 9.
2
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.基于淋巴细胞亚群绝对计数构建的预测抗 PD-1 抑制剂治疗晚期非小细胞肺癌患者疗效和预后的两个列线图。
Cancer Immunol Immunother. 2024 Jun 4;73(8):152. doi: 10.1007/s00262-024-03738-x.
3
The advanced lung cancer inflammation index (ALI) predicted the postoperative survival rate of patients with non-small cell lung cancer and the construction of a nomogram model.高级肺癌炎症指数 (ALI) 预测了非小细胞肺癌患者的术后生存率和列线图模型的构建。
World J Surg Oncol. 2024 Jun 14;22(1):158. doi: 10.1186/s12957-024-03432-3.
4
Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.建立列线图预测接受抗 PD-1 抗体治疗的非小细胞肺癌患者的治疗反应和预后。
Cancer Immunol Immunother. 2021 Feb;70(2):533-546. doi: 10.1007/s00262-020-02710-9. Epub 2020 Aug 27.
5
A validated nomogram integrating baseline peripheral T-lymphocyte subsets and NK cells for predicting survival in stage I-IIIA non-small cell lung cancer after resection.一种经过验证的列线图,整合基线外周血T淋巴细胞亚群和自然杀伤细胞,用于预测I-IIIA期非小细胞肺癌切除术后的生存情况。
Ann Transl Med. 2022 Mar;10(5):250. doi: 10.21037/atm-21-6347.
6
Prognostic nomogram based on pre-treatment HALP score for patients with advanced non-small cell lung cancer.基于治疗前 HALP 评分的晚期非小细胞肺癌患者预后列线图。
Clinics (Sao Paulo). 2024 May 11;79:100371. doi: 10.1016/j.clinsp.2024.100371. eCollection 2024.
7
Development and Validation of a Novel Survival Prediction Model in Patients With Spinal Metastasis From Non-small Cell Lung Cancer.开发和验证一种新型生存预测模型在非小细胞肺癌脊柱转移患者中的应用。
Spine (Phila Pa 1976). 2019 Feb 15;44(4):246-257. doi: 10.1097/BRS.0000000000002816.
8
Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.预测接受抗 PD-1 联合化疗加或不加抗血管生成治疗的晚期非小细胞肺癌患者生存的新型列线图。
Front Immunol. 2023 Nov 8;14:1297188. doi: 10.3389/fimmu.2023.1297188. eCollection 2023.
9
Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.纳入治疗前外周血标志物的非小细胞肺癌患者总生存预测列线图。
Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1214-1222. doi: 10.1093/ejcts/ezx462.
10
A novel LASSO-derived prognostic model predicting survival for non-small cell lung cancer patients with M1a diseases.一种基于新型 LASSO 算法的预后模型,可预测 M1a 期非小细胞肺癌患者的生存情况。
Cancer Med. 2022 Mar;11(6):1561-1572. doi: 10.1002/cam4.4560. Epub 2022 Feb 6.

引用本文的文献

1
Peripheral T Lymphocyte Predicts the Prognosis of Gastric Cancer Patients Undergoing Radical Gastrectomy: A Multicenter Retrospective Cohort Study.外周血T淋巴细胞预测胃癌根治术后患者的预后:一项多中心回顾性队列研究
J Inflamm Res. 2024 Dec 8;17:10599-10612. doi: 10.2147/JIR.S494342. eCollection 2024.
2
Predictive value of lymphocyte subsets and lymphocyte-to-monocyte ratio in assessing the efficacy of neoadjuvant therapy in breast cancer.淋巴细胞亚群和淋巴细胞与单核细胞比值对评估乳腺癌新辅助治疗疗效的预测价值。
Sci Rep. 2024 Jun 4;14(1):12799. doi: 10.1038/s41598-024-61632-z.
3
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
基于淋巴细胞亚群绝对计数构建的预测抗 PD-1 抑制剂治疗晚期非小细胞肺癌患者疗效和预后的两个列线图。
Cancer Immunol Immunother. 2024 Jun 4;73(8):152. doi: 10.1007/s00262-024-03738-x.